董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kelvin Neu | 男 | Director | 51 | 29.65万美元 | 未持股 | 2025-11-16 |
| Alessandra Cesano | 女 | Director | 65 | 81.02万美元 | 未持股 | 2025-11-16 |
| Susan Mahony | 女 | Director | 60 | 31.46万美元 | 未持股 | 2025-11-16 |
| Kenneth Galbraith | 男 | Chair of the Board,Chief Executive Officer and President | 62 | 525.36万美元 | 未持股 | 2025-11-16 |
| Gregory A. Ciongoli | 男 | Director | 49 | 未披露 | 未持股 | 2025-11-16 |
| Carlos Campoy | 男 | Director | 61 | 30.65万美元 | 未持股 | 2025-11-16 |
| Oleg Nodelman | 男 | Director | 48 | 未披露 | 未持股 | 2025-11-16 |
| Robert E. Landry | 男 | Director | 61 | 未披露 | 未持股 | 2025-11-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leone Patterson | 女 | Executive Vice President, Chief Business Officer, Principal Accounting Officer and Chief Financial Officer | 62 | 290.80万美元 | 未持股 | 2025-11-16 |
| Kenneth Galbraith | 男 | Chair of the Board,Chief Executive Officer and President | 62 | 525.36万美元 | 未持股 | 2025-11-16 |
| Paul A. Moore | 男 | Chief Scientific Officer | 59 | 198.68万美元 | 未持股 | 2025-11-16 |
| Jeffrey Smith | 男 | Executive Vice President and Chief Medical Officer | 66 | 未披露 | 未持股 | 2025-11-16 |
董事简历
中英对照 | 中文 | 英文- Kelvin Neu
-
Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
Kelvin Neu has served as a member of Board of Directors since March 2020. Dr. Neu is Founder and Chief of Herringbone, a life sciences innovation practice established in February 2022. Dr. Neu is also Co Founder and Director of QDX Pte Ltd and QDX Technologies Pte Ltd (which work in the area of computational drug discovery) and XBI Biosciences LLC (a therapeutics development company). Previoly, Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, where he worked from 2004 until 2021. Dr. Neu previoly served on the board of directors of IGM Biosciences from 2019 to 2021, Prelude Therapeutics from 2016 to 2021, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khy Prize for graduating first in his department of Molecular Biology. - Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
- Kelvin Neu has served as a member of Board of Directors since March 2020. Dr. Neu is Founder and Chief of Herringbone, a life sciences innovation practice established in February 2022. Dr. Neu is also Co Founder and Director of QDX Pte Ltd and QDX Technologies Pte Ltd (which work in the area of computational drug discovery) and XBI Biosciences LLC (a therapeutics development company). Previoly, Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, where he worked from 2004 until 2021. Dr. Neu previoly served on the board of directors of IGM Biosciences from 2019 to 2021, Prelude Therapeutics from 2016 to 2021, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khy Prize for graduating first in his department of Molecular Biology.
- Alessandra Cesano
-
Alessandra Cesano于2019年7月加入ESSA担任首席医疗官。此前，她曾于2015年7月至2019年6月担任NanoString Inc.的首席医疗官，在那里她专注于开发用于表征和测量免疫反应/耐药性机制的转化和诊断性多丛分析。任职NanoString公司之前，她曾担任Cleave Biosciences公司的首席医疗官，此前曾担任Nodality公司的首席医疗官兼首席运营官，在那里她曾建立和领导研发集团，同时为公司提供整体临床愿景。1998年至2008年，Cesano博士曾在安进公司、BiogenInc.（前身为Biogen Idec和SmithKline Beecham Pharmaceuticals）担任多个管理职位，在那里她帮助推进各种肿瘤药物的后期开发和FDA批准。在她职业生涯的早期，Cesano博士花了12年时间进行肿瘤免疫学研究，包括在威斯达研究所（Wistar Institute）工作了9年，这是一个与宾夕法尼亚大学（University of Pennsylvania）有联系的新华保险基础癌症中心。她也是几个专业和科学协会的成员，包括ASCO、ESMO、ASH、EHA、AACR和癌症免疫治疗协会（“；SITC”；）。在后者中，她担任SITC行业委员会的联合主席，《癌症免疫治疗杂志》生物标志物部分的副编辑，SITC生物标志物工作组的联合主席，并当选为SITC2020-2023年任期的无任所董事。在她的职业生涯中，Cesano博士是130多个出版物的作者。Cesano博士在都灵大学（University of Turin）以优异成绩获得医学博士学位、肿瘤学董事会认证和肿瘤免疫学博士学位。
Alessandra Cesano has served as a member of Board of Directors since February 2024. Dr. Cesano has served as an advisor to General Catalyst, a venture capital and investment firm, since February 2025. Dr. Cesano served as the Chief Medical Officer of ESSA Pharma Inc., a pharmaceutical company developing therapies for the treatment of prostate cancer, from July 2019 to May 2025. Previoly, Dr. Cesano was the Chief Medical Officer of NanoString Technologies, Inc., a biotechnology company that develops translational research tools, from July 2015 to July 2019, where she foced on development of translational and diagnostic multi plexed assays for the characterization and measurement of mechanisms of immune response and resistance. Prior to NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc., a biopharmaceutical company focing on protein therapies for the treatment of cancer and neurodegenerative diseases, and before that she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the Research & Development group, while providing the overall clinical vision for the organization. Dr. Cesano has also held vario management positions at Amgen Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where she helped to advance vario oncology drugs through late stage development and U.S. Food and Drug Administration ("FDA") approvals. She currently serves as associate editor for the Biomarker section of the Jnal for ImmunoTherapy of Cancer and co chair of the Society for Immunotherapy of Cancer (SITC) regulatory committee. She has been an author on more than 140 publications. Dr. Cesano has served as a director at Puma Biotechnology, Inc. since July 2022 and as a director of Summit Therapeutics Inc. since November 2022. Dr. Cesano received an M.D. summa cum laude, a board certification in oncology and a Ph.D. in Tumor Immunology from the University of Turin, Italy. - Alessandra Cesano于2019年7月加入ESSA担任首席医疗官。此前，她曾于2015年7月至2019年6月担任NanoString Inc.的首席医疗官，在那里她专注于开发用于表征和测量免疫反应/耐药性机制的转化和诊断性多丛分析。任职NanoString公司之前，她曾担任Cleave Biosciences公司的首席医疗官，此前曾担任Nodality公司的首席医疗官兼首席运营官，在那里她曾建立和领导研发集团，同时为公司提供整体临床愿景。1998年至2008年，Cesano博士曾在安进公司、BiogenInc.（前身为Biogen Idec和SmithKline Beecham Pharmaceuticals）担任多个管理职位，在那里她帮助推进各种肿瘤药物的后期开发和FDA批准。在她职业生涯的早期，Cesano博士花了12年时间进行肿瘤免疫学研究，包括在威斯达研究所（Wistar Institute）工作了9年，这是一个与宾夕法尼亚大学（University of Pennsylvania）有联系的新华保险基础癌症中心。她也是几个专业和科学协会的成员，包括ASCO、ESMO、ASH、EHA、AACR和癌症免疫治疗协会（“；SITC”；）。在后者中，她担任SITC行业委员会的联合主席，《癌症免疫治疗杂志》生物标志物部分的副编辑，SITC生物标志物工作组的联合主席，并当选为SITC2020-2023年任期的无任所董事。在她的职业生涯中，Cesano博士是130多个出版物的作者。Cesano博士在都灵大学（University of Turin）以优异成绩获得医学博士学位、肿瘤学董事会认证和肿瘤免疫学博士学位。
- Alessandra Cesano has served as a member of Board of Directors since February 2024. Dr. Cesano has served as an advisor to General Catalyst, a venture capital and investment firm, since February 2025. Dr. Cesano served as the Chief Medical Officer of ESSA Pharma Inc., a pharmaceutical company developing therapies for the treatment of prostate cancer, from July 2019 to May 2025. Previoly, Dr. Cesano was the Chief Medical Officer of NanoString Technologies, Inc., a biotechnology company that develops translational research tools, from July 2015 to July 2019, where she foced on development of translational and diagnostic multi plexed assays for the characterization and measurement of mechanisms of immune response and resistance. Prior to NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc., a biopharmaceutical company focing on protein therapies for the treatment of cancer and neurodegenerative diseases, and before that she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the Research & Development group, while providing the overall clinical vision for the organization. Dr. Cesano has also held vario management positions at Amgen Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where she helped to advance vario oncology drugs through late stage development and U.S. Food and Drug Administration ("FDA") approvals. She currently serves as associate editor for the Biomarker section of the Jnal for ImmunoTherapy of Cancer and co chair of the Society for Immunotherapy of Cancer (SITC) regulatory committee. She has been an author on more than 140 publications. Dr. Cesano has served as a director at Puma Biotechnology, Inc. since July 2022 and as a director of Summit Therapeutics Inc. since November 2022. Dr. Cesano received an M.D. summa cum laude, a board certification in oncology and a Ph.D. in Tumor Immunology from the University of Turin, Italy.
- Susan Mahony
-
Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
Susan Mahony has served as a member of Board of Directors since June 2019 and as Lead Independent Director of Board of Directors since December 2023. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until Augt 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resces, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering Plough, Amgen, and Bristol Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previoly served on the board of directors of Horizon Therapeutics Public Limited Company from Augt 2019 to October 2023 (acquired by Amgen Inc.) and on the board of directors of Vifor Pharma from May 2019 until Augt 2022 (acquired by CSL Limited). Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Biness School. Dr. Mahony is NACD Directorship Certified[]. - Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
- Susan Mahony has served as a member of Board of Directors since June 2019 and as Lead Independent Director of Board of Directors since December 2023. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until Augt 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resces, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering Plough, Amgen, and Bristol Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previoly served on the board of directors of Horizon Therapeutics Public Limited Company from Augt 2019 to October 2023 (acquired by Amgen Inc.) and on the board of directors of Vifor Pharma from May 2019 until Augt 2022 (acquired by CSL Limited). Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Biness School. Dr. Mahony is NACD Directorship Certified[].
- Kenneth Galbraith
-
Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
Kenneth Galbraith has served as Chief Executive Officer and Chair of Board of Directors since January 2022. In addition, Mr. Galbraith has served as President since June 2023 and previoly served as President from January 2022 to Augt 2022, and served as interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Investment Management Limited ("SIML", a subsidiary of Syncona Limited, a company that builds a portfolio of life sciences binesses), from April 2021 until January 2022. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previoly, he joined Ventures st Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures st Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. - Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
- Kenneth Galbraith has served as Chief Executive Officer and Chair of Board of Directors since January 2022. In addition, Mr. Galbraith has served as President since June 2023 and previoly served as President from January 2022 to Augt 2022, and served as interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Investment Management Limited ("SIML", a subsidiary of Syncona Limited, a company that builds a portfolio of life sciences binesses), from April 2021 until January 2022. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previoly, he joined Ventures st Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures st Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia.
- Gregory A. Ciongoli
-
Gregory A. Ciongoli是美国公民。
Gregory A. Ciongoli has served as a member of Board of Directors since Augt 2025. Mr. Ciongoli is currently the Founder and Managing partner at Adiumentum Capital Management, a Boston based investment firm, and has served in that role since March 2024. Mr. Ciongoli has also served on the board of directors of Atara Biotherapeutics since September 2024, including as board chair since September 2025. Mr. Ciongoli served as a Public Group Investing Partner at the Baupost Group from 2007 to 2024. Mr. Ciongoli has served on the board of directors of Pelotero Corp. since March 2020, 33[rd] Team since September 2022, and Wavebreak Therapeutics since Augt 2017, and served as a board observer at Viasat Inc. from October 2018 to May 2023. In addition, Mr. Ciongoli previoly served as a board observer at Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Orexigen Therapeutics and Translate Bio. Earlier in his career, Mr. Ciongoli held the position of Director in the Event Driven Equity Group at Sowood Capital Management from 2005 to 2007 and worked as an Investment Analyst at Vinik Asset Management from 2003 to 2005 and at Thomas H. Lee Partners from 1999 to 2001. Mr. Ciongoli began his career as a Financial Analyst in the Healthcare Investment Banking Group at Goldman, Sachs & Co. from 1997 to 1999. Mr. Ciongoli also serves as the Chair of the Advisory Board for the James Madison Program in American Ideals and Institutions at Princeton University, and is actively involved in a number of local not for profit organizations. Mr. Ciongoli earned a Master in Biness Administration degree from Harvard Biness School in June 2003 and earned his Bachelor of Arts degree from the Woodrow Wilson School of Public and International Affairs at Princeton University in 1997. - Gregory A. Ciongoli是美国公民。
- Gregory A. Ciongoli has served as a member of Board of Directors since Augt 2025. Mr. Ciongoli is currently the Founder and Managing partner at Adiumentum Capital Management, a Boston based investment firm, and has served in that role since March 2024. Mr. Ciongoli has also served on the board of directors of Atara Biotherapeutics since September 2024, including as board chair since September 2025. Mr. Ciongoli served as a Public Group Investing Partner at the Baupost Group from 2007 to 2024. Mr. Ciongoli has served on the board of directors of Pelotero Corp. since March 2020, 33[rd] Team since September 2022, and Wavebreak Therapeutics since Augt 2017, and served as a board observer at Viasat Inc. from October 2018 to May 2023. In addition, Mr. Ciongoli previoly served as a board observer at Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Orexigen Therapeutics and Translate Bio. Earlier in his career, Mr. Ciongoli held the position of Director in the Event Driven Equity Group at Sowood Capital Management from 2005 to 2007 and worked as an Investment Analyst at Vinik Asset Management from 2003 to 2005 and at Thomas H. Lee Partners from 1999 to 2001. Mr. Ciongoli began his career as a Financial Analyst in the Healthcare Investment Banking Group at Goldman, Sachs & Co. from 1997 to 1999. Mr. Ciongoli also serves as the Chair of the Advisory Board for the James Madison Program in American Ideals and Institutions at Princeton University, and is actively involved in a number of local not for profit organizations. Mr. Ciongoli earned a Master in Biness Administration degree from Harvard Biness School in June 2003 and earned his Bachelor of Arts degree from the Woodrow Wilson School of Public and International Affairs at Princeton University in 1997.
- Carlos Campoy
-
Carlos Campoy，自2023年6月起担任Zymeworks Inc.董事会成员。Campoy先生于2020年3月至2022年9月期间担任CytomX医疗，Inc.的首席财务官。在加入CytomX医疗之前，Campoy先生于2018年12月至2019年11月期间担任Alder BioPharmaceuticals，Inc.的首席财务官，该公司是一家于2019年10月被Lundbeck A/S收购的上市生物制药公司。在Alder BioPharmaceuticals任职期间，Campoy先生领导了这家金融机构，并为该公司的主导项目eptinezumab的商业启动做好了准备。在加入Alder BioPharmaceuticals之前，Campoy先生于2017年9月至2018年12月期间担任精品金融咨询公司Think Forwards的合伙人。在Think Forwards任职之前，Campoy先生曾于2014年7月至2016年11月在Allergan plc担任财务副总裁。在加入艾尔建之前，Campoy先生于1996年至2014年在礼来公司担任高级财务领导职务，包括礼来日本K.K.的首席财务官。Campoy先生拥有注册管理会计师（CMA）称号。Campoy先生在印第安纳大学获得金融和决策信息系统工商管理硕士学位，在巴西圣保罗的Faculdade de Ci ê ncias Cont á beis e de Administra o de Empresas de Tup （FACCAT）获得管理学士学位。
Carlos Campoy has served as a member of Board of Directors since June 2023. Mr. Campoy served as Chief Financial Officer of CytomX Therapeutics, Inc. from March 2020 through September 2022. Prior to CytomX Therapeutics, Mr. Campoy served as the Chief Financial Officer of Alder BioPharmaceuticals, Inc., a public biopharmaceutical company acquired in October 2019 by Lundbeck A/S, from December 2018 to November 2019. During his time at Alder BioPharmaceuticals, Mr. Campoy led the finance organization and readied the company for commercial launch of its lead program, eptinezumab. Prior to Alder BioPharmaceuticals, Mr. Campoy was a partner at Think Forwards, a boutique financial consulting firm, from September 2017 to December 2018. Prior to his position at Think Forwards, Mr. Campoy held the role of vice president of finance at Allergan plc from July 2014 to November 2016. Prior to joining Allergan, Mr. Campoy held senior financial leadership positions at Eli Lilly and Company from 1996 to 2014, including Chief Financial Officer of Eli Lilly Japan K.K. Mr. Campoy is NACD Directorship Certified[] and holds a Certified Management Accountant (CMA) designation. Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade de Ciências Contábeis e de Administrao de Empresas de Tup (FACCAT), in So Paulo, Brazil. - Carlos Campoy，自2023年6月起担任Zymeworks Inc.董事会成员。Campoy先生于2020年3月至2022年9月期间担任CytomX医疗，Inc.的首席财务官。在加入CytomX医疗之前，Campoy先生于2018年12月至2019年11月期间担任Alder BioPharmaceuticals，Inc.的首席财务官，该公司是一家于2019年10月被Lundbeck A/S收购的上市生物制药公司。在Alder BioPharmaceuticals任职期间，Campoy先生领导了这家金融机构，并为该公司的主导项目eptinezumab的商业启动做好了准备。在加入Alder BioPharmaceuticals之前，Campoy先生于2017年9月至2018年12月期间担任精品金融咨询公司Think Forwards的合伙人。在Think Forwards任职之前，Campoy先生曾于2014年7月至2016年11月在Allergan plc担任财务副总裁。在加入艾尔建之前，Campoy先生于1996年至2014年在礼来公司担任高级财务领导职务，包括礼来日本K.K.的首席财务官。Campoy先生拥有注册管理会计师（CMA）称号。Campoy先生在印第安纳大学获得金融和决策信息系统工商管理硕士学位，在巴西圣保罗的Faculdade de Ci ê ncias Cont á beis e de Administra o de Empresas de Tup （FACCAT）获得管理学士学位。
- Carlos Campoy has served as a member of Board of Directors since June 2023. Mr. Campoy served as Chief Financial Officer of CytomX Therapeutics, Inc. from March 2020 through September 2022. Prior to CytomX Therapeutics, Mr. Campoy served as the Chief Financial Officer of Alder BioPharmaceuticals, Inc., a public biopharmaceutical company acquired in October 2019 by Lundbeck A/S, from December 2018 to November 2019. During his time at Alder BioPharmaceuticals, Mr. Campoy led the finance organization and readied the company for commercial launch of its lead program, eptinezumab. Prior to Alder BioPharmaceuticals, Mr. Campoy was a partner at Think Forwards, a boutique financial consulting firm, from September 2017 to December 2018. Prior to his position at Think Forwards, Mr. Campoy held the role of vice president of finance at Allergan plc from July 2014 to November 2016. Prior to joining Allergan, Mr. Campoy held senior financial leadership positions at Eli Lilly and Company from 1996 to 2014, including Chief Financial Officer of Eli Lilly Japan K.K. Mr. Campoy is NACD Directorship Certified[] and holds a Certified Management Accountant (CMA) designation. Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade de Ciências Contábeis e de Administrao de Empresas de Tup (FACCAT), in So Paulo, Brazil.
- Oleg Nodelman
-
Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
Oleg Nodelman has served as a member of Board of Directors since February 2025. Since October 2013, Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech foced investment advisory firm established in 2013, and one of principal stockholders. Previoly, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman has served on the board of Galapagos NV since October 2024 and AnaptysBio since April 2021. He previoly served on the board of directors of Prothena Corporation plc from December 2019 to December 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021. - Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
- Oleg Nodelman has served as a member of Board of Directors since February 2025. Since October 2013, Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech foced investment advisory firm established in 2013, and one of principal stockholders. Previoly, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman has served on the board of Galapagos NV since October 2024 and AnaptysBio since April 2021. He previoly served on the board of directors of Prothena Corporation plc from December 2019 to December 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021.
- Robert E. Landry
-
Robert E. Landry，自2019年1月起担任财务执行副总裁，2013年10月起担任首席财务官。2013年9月至2018年12月，他担任财务高级副总裁。此前，他曾担任Pfizer Inc.的高级副总裁兼财务主管（从2012年10月到2013年8月），以及Pfizer的多元化业务财务高级副总裁（从2009年10月到2012年10月）。在此之前，Landry先生在Wyeth担任多个职位，该公司于2009年10月被辉瑞公司收购，2007年至2009年担任财务主管和首席公司官，2006年至2007年担任惠氏澳大利亚分公司的药品营销和销售总监，2004年至2006年担任惠氏澳大利亚和新西兰分公司的首席财务官。Landry先生拥有圣母大学会计学学士学位。
Robert E. Landry has served as a member of Board of Directors since Augt 2025. Mr. Landry served as the Executive Vice President and Chief Financial Officer at Regeneron Pharmaceuticals, Inc., from September 2013 to January 2024. Prior to his time at Regeneron, Mr. Landry served from January 1988 to Augt 2013 as the Senior Vice President, Treasurer, Senior Vice President, Finance, and in other vario corporate roles at Pfizer (formerly Wyeth). Mr. Landry started his career at Coopers & Lybrand, now PricewaterhoeCoopers LLP. Mr. Landry also currently serves on the board of directors of Cytokinetics, Inc., a late stage biopharmaceutical company. Mr. Landry is a Certified Public Accountant in New York (inactive) and attended the University of Notre Dame, where he earned a B.B.A. in accounting in 1986. - Robert E. Landry，自2019年1月起担任财务执行副总裁，2013年10月起担任首席财务官。2013年9月至2018年12月，他担任财务高级副总裁。此前，他曾担任Pfizer Inc.的高级副总裁兼财务主管（从2012年10月到2013年8月），以及Pfizer的多元化业务财务高级副总裁（从2009年10月到2012年10月）。在此之前，Landry先生在Wyeth担任多个职位，该公司于2009年10月被辉瑞公司收购，2007年至2009年担任财务主管和首席公司官，2006年至2007年担任惠氏澳大利亚分公司的药品营销和销售总监，2004年至2006年担任惠氏澳大利亚和新西兰分公司的首席财务官。Landry先生拥有圣母大学会计学学士学位。
- Robert E. Landry has served as a member of Board of Directors since Augt 2025. Mr. Landry served as the Executive Vice President and Chief Financial Officer at Regeneron Pharmaceuticals, Inc., from September 2013 to January 2024. Prior to his time at Regeneron, Mr. Landry served from January 1988 to Augt 2013 as the Senior Vice President, Treasurer, Senior Vice President, Finance, and in other vario corporate roles at Pfizer (formerly Wyeth). Mr. Landry started his career at Coopers & Lybrand, now PricewaterhoeCoopers LLP. Mr. Landry also currently serves on the board of directors of Cytokinetics, Inc., a late stage biopharmaceutical company. Mr. Landry is a Certified Public Accountant in New York (inactive) and attended the University of Notre Dame, where he earned a B.B.A. in accounting in 1986.
高管简历
中英对照 | 中文 | 英文- Leone Patterson
Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升，我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官，并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月，帕特森女士担任诊断公司Diadexus，Inc.的首席财务官，负责监督该公司的财务职能。在此之前，帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals，Inc.的Vice President和首席财务官，直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购，她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp，Inc.（一家数据管理和存储公司）的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis，Inc（一家生物制药公司）金融Vice President。在Exelixis之前，Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年，她曾担任Chiron公司（生物技术公司，现为Novartis AG公司的一部分）的多种职务，包括Vice President、公司总会计师。从1989年到1999年，她曾任职会计师事务所KPMG的审计实践，在那里她曾担任多种职务，包括高级经理。Patterson女士目前在Nkarta，Inc.董事会任职。Patterson女士在查普曼大学（Chapman University）获得工商管理与会计学学士学位，并在圣玛丽学院（St.Mary’；s College）获得执行工商管理硕士学位。Patterson女士也是一名注册会计师（非活跃状态）。
Leone Patterson joined Zymeworks in September 2024 and serves as Executive Vice President, Chief Biness Officer and Chief Financial Officer. Ms. Patterson served as Chief Financial Officer and Biness Officer of Tenaya Therapeutics, Inc. from June 2021 until Augt 2024. Prior to joining Tenaya Therapeutics, Inc., Ms. Patterson joined Adverum Biotechnologies, Inc., a public clinical stage gene therapy company, in June 2016 as the Chief Financial Officer and also served as Chief Executive Officer from May 2018 to June 2020, director from October 2018 to June 2020, and President from July 2020 to June 2021. Ms. Patterson has held vario senior positions at Diadex, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc., Exelixis, Inc., Novartis AG, Chiron (acquired by Novartis AG), and KPMG. Ms. Patterson has served on the board of directors and as the chair of the audit committee of Nkarta, Inc., a publicly traded biotechnology company, since April 2020. In addition, Ms. Patterson has served on the board of directors and as the chair of the audit committee of Kalaris Therapeutics Inc., a publicly traded biotechnology company, since April 2025. She previoly served as a member of the board of directors of Eliem Therapeutics, Inc. from March 2021 to December 2024 and Adverum Biotechnologies, Inc. from October 2018 to June 2020, both publicly traded biotechnology companies, and as a member of the board of directors of Oxford Biomedica (UK) Limited, a publicly traded contract development and manufacturing organization foced on cell and gene therapy, from March 2023 to December 2024. Ms. Patterson holds a B.S. in Biness Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary's College. Ms. Patterson is also a Certified Public Accountant (inactive stat).- Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升，我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官，并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月，帕特森女士担任诊断公司Diadexus，Inc.的首席财务官，负责监督该公司的财务职能。在此之前，帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals，Inc.的Vice President和首席财务官，直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购，她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp，Inc.（一家数据管理和存储公司）的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis，Inc（一家生物制药公司）金融Vice President。在Exelixis之前，Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年，她曾担任Chiron公司（生物技术公司，现为Novartis AG公司的一部分）的多种职务，包括Vice President、公司总会计师。从1989年到1999年，她曾任职会计师事务所KPMG的审计实践，在那里她曾担任多种职务，包括高级经理。Patterson女士目前在Nkarta，Inc.董事会任职。Patterson女士在查普曼大学（Chapman University）获得工商管理与会计学学士学位，并在圣玛丽学院（St.Mary’；s College）获得执行工商管理硕士学位。Patterson女士也是一名注册会计师（非活跃状态）。
- Leone Patterson joined Zymeworks in September 2024 and serves as Executive Vice President, Chief Biness Officer and Chief Financial Officer. Ms. Patterson served as Chief Financial Officer and Biness Officer of Tenaya Therapeutics, Inc. from June 2021 until Augt 2024. Prior to joining Tenaya Therapeutics, Inc., Ms. Patterson joined Adverum Biotechnologies, Inc., a public clinical stage gene therapy company, in June 2016 as the Chief Financial Officer and also served as Chief Executive Officer from May 2018 to June 2020, director from October 2018 to June 2020, and President from July 2020 to June 2021. Ms. Patterson has held vario senior positions at Diadex, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc., Exelixis, Inc., Novartis AG, Chiron (acquired by Novartis AG), and KPMG. Ms. Patterson has served on the board of directors and as the chair of the audit committee of Nkarta, Inc., a publicly traded biotechnology company, since April 2020. In addition, Ms. Patterson has served on the board of directors and as the chair of the audit committee of Kalaris Therapeutics Inc., a publicly traded biotechnology company, since April 2025. She previoly served as a member of the board of directors of Eliem Therapeutics, Inc. from March 2021 to December 2024 and Adverum Biotechnologies, Inc. from October 2018 to June 2020, both publicly traded biotechnology companies, and as a member of the board of directors of Oxford Biomedica (UK) Limited, a publicly traded contract development and manufacturing organization foced on cell and gene therapy, from March 2023 to December 2024. Ms. Patterson holds a B.S. in Biness Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary's College. Ms. Patterson is also a Certified Public Accountant (inactive stat).
- Kenneth Galbraith
Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
Kenneth Galbraith has served as Chief Executive Officer and Chair of Board of Directors since January 2022. In addition, Mr. Galbraith has served as President since June 2023 and previoly served as President from January 2022 to Augt 2022, and served as interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Investment Management Limited ("SIML", a subsidiary of Syncona Limited, a company that builds a portfolio of life sciences binesses), from April 2021 until January 2022. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previoly, he joined Ventures st Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures st Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia.- Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
- Kenneth Galbraith has served as Chief Executive Officer and Chair of Board of Directors since January 2022. In addition, Mr. Galbraith has served as President since June 2023 and previoly served as President from January 2022 to Augt 2022, and served as interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Investment Management Limited ("SIML", a subsidiary of Syncona Limited, a company that builds a portfolio of life sciences binesses), from April 2021 until January 2022. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previoly, he joined Ventures st Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures st Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia.
- Paul A. Moore
Paul A. Moore，2022年7月加入Zymeworks，担任Zymeworks Inc.首席科学官。Moore博士在生物技术研究领域的生物制剂药物发现和开发方面拥有超过25年的美国经验。他在职业生涯中的努力导致了一系列FDA批准和临床阶段的生物制剂的发现和开发，用于患有难以治疗的癌症和自身免疫性疾病的患者。在加入Zymeworks之前，Moore博士于2008年4月至2022年7月在MacroGenics担任细胞生物学和免疫学副总裁，领导着一个由大约50名研究人员组成的团队，从事基于抗体的疗法的发现、临床前验证和临床开发，包括双特异性抗体和抗体药物偶联物。Moore博士支持的产品组合包括FDA批准的用于治疗HER2 +乳腺癌的Margenza（margetuximab-cmkb）、用于治疗默克尔细胞癌的Zynyz（retifanlimab-dlwr）和用于延缓I型糖尿病发病的Tzield（teplizumab-mzwv）。在加入MacroGenics之前，Moore博士于2005年5月至2008年4月担任Celera的细胞生物学总监，负责监督利用基于蛋白质组学的发现来验证适用于基于抗体的疗法的新癌症靶点的研究。Moore博士在Human Genome Sciences（HGS）开始了他的工业生涯，在研究领域拥有多个头衔，最终成为主要产品开发总监，在那里他管理了各种基于基因组的靶点发现计划，包括导致发现、开发、批准和商业化用于治疗系统性红斑狼疮的Benlysta（belimumab）的努力。Moore博士拥有广泛的研究记录，与他人合著了超过75篇同行评审的手稿，并且是50多项已发布的美国专利的指定共同发明人。Moore博士拥有格拉斯哥大学分子遗传学博士学位，曾在新泽西州纳特利的罗氏分子生物学研究所从事博士后工作，还拥有斯特拉斯克莱德大学生物技术学位。
Paul A. Moore joined Zymeworks in July 2022 and serves as Chief Scientific Officer. Dr. Moore has more than 25 years of U.S. based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA approved and clinical stage biologics for patients with difficult to treat cancers and autoimmune conditions. Prior to joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics from April 2008 to July 2022, leading a team of approximately 50 researchers engaged in the discovery, preclinical validation and clinical development of antibody based therapeutics, including bispecific antibodies and antibody drug conjugates. Among the portfolio supported by Dr. Moore re FDA approved Margenza (margetuximab cmkb) for treatment of HER2+ breast cancer, Zynyz (retifanlimab dlwr) for treatment of Merkel cell carcinoma and Tzield (teplizumab mzwv) to delay onset of type I diabetes. Prior to joining MacroGenics, Dr. Moore was Director of Cell Biology at Celera from May 2005 to April 2008, where he oversaw research leveraging proteomic based discoveries to validate novel cancer targets suitable for antibody-based therapeutics. Dr. Moore began his industrial career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued U.S. patents. Dr. Moore holds a Ph.D. in Molecular Genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde.- Paul A. Moore，2022年7月加入Zymeworks，担任Zymeworks Inc.首席科学官。Moore博士在生物技术研究领域的生物制剂药物发现和开发方面拥有超过25年的美国经验。他在职业生涯中的努力导致了一系列FDA批准和临床阶段的生物制剂的发现和开发，用于患有难以治疗的癌症和自身免疫性疾病的患者。在加入Zymeworks之前，Moore博士于2008年4月至2022年7月在MacroGenics担任细胞生物学和免疫学副总裁，领导着一个由大约50名研究人员组成的团队，从事基于抗体的疗法的发现、临床前验证和临床开发，包括双特异性抗体和抗体药物偶联物。Moore博士支持的产品组合包括FDA批准的用于治疗HER2 +乳腺癌的Margenza（margetuximab-cmkb）、用于治疗默克尔细胞癌的Zynyz（retifanlimab-dlwr）和用于延缓I型糖尿病发病的Tzield（teplizumab-mzwv）。在加入MacroGenics之前，Moore博士于2005年5月至2008年4月担任Celera的细胞生物学总监，负责监督利用基于蛋白质组学的发现来验证适用于基于抗体的疗法的新癌症靶点的研究。Moore博士在Human Genome Sciences（HGS）开始了他的工业生涯，在研究领域拥有多个头衔，最终成为主要产品开发总监，在那里他管理了各种基于基因组的靶点发现计划，包括导致发现、开发、批准和商业化用于治疗系统性红斑狼疮的Benlysta（belimumab）的努力。Moore博士拥有广泛的研究记录，与他人合著了超过75篇同行评审的手稿，并且是50多项已发布的美国专利的指定共同发明人。Moore博士拥有格拉斯哥大学分子遗传学博士学位，曾在新泽西州纳特利的罗氏分子生物学研究所从事博士后工作，还拥有斯特拉斯克莱德大学生物技术学位。
- Paul A. Moore joined Zymeworks in July 2022 and serves as Chief Scientific Officer. Dr. Moore has more than 25 years of U.S. based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA approved and clinical stage biologics for patients with difficult to treat cancers and autoimmune conditions. Prior to joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics from April 2008 to July 2022, leading a team of approximately 50 researchers engaged in the discovery, preclinical validation and clinical development of antibody based therapeutics, including bispecific antibodies and antibody drug conjugates. Among the portfolio supported by Dr. Moore re FDA approved Margenza (margetuximab cmkb) for treatment of HER2+ breast cancer, Zynyz (retifanlimab dlwr) for treatment of Merkel cell carcinoma and Tzield (teplizumab mzwv) to delay onset of type I diabetes. Prior to joining MacroGenics, Dr. Moore was Director of Cell Biology at Celera from May 2005 to April 2008, where he oversaw research leveraging proteomic based discoveries to validate novel cancer targets suitable for antibody-based therapeutics. Dr. Moore began his industrial career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued U.S. patents. Dr. Moore holds a Ph.D. in Molecular Genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde.
- Jeffrey Smith
Jeffrey Smith，于2023年1月加入Zymeworks，担任早期开发高级副总裁，并于2024年1月晋升为执行副总裁兼首席医疗官。他的总部设在爱尔兰都柏林的Zymeworks Inc.欧洲中心。史密斯博士曾在制药行业担任多个高级职位。此前，史密斯博士于2017年3月至2019年10月担任爱尔兰都柏林Alder Biopharmaceuticals Inc.的董事总经理，并于2012年至2017年3月担任美国西雅图Alder Biopharmaceuticals Inc.的转化医学高级副总裁。Smith博士负责eptinezumab（用于偏头痛的抗CGRP抗体）和clazakizumab（用于类风湿性关节炎和癌症恶病质的抗IL-6抗体）的临床开发（I-III期）。史密斯博士也是Alder Biopharmaceutcials Inc（成立于2004年）的创始人。史密斯博士在英国伦敦大学获得了工商管理硕士学位和医学博士学位，并且是伦敦皇家内科医学院的院士。
Jeffrey Smith joined Zymeworks in January 2023 as Senior Vice President, Early Stage Development and was promoted to Executive Vice President and Chief Medical Officer in January 2024. He is based at European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical indtry. Previoly, Dr. Smith served as the Managing Director of Alder Biopharmaceuticals Inc. in Dublin, Ireland from March 2017 to October 2019, and as Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc. in Seattle, U.S. from 2012 to March 2017. Dr. Smith was responsible for the clinical development (phase I III) of eptinezumab (anti CGRP antibody for migraine) and clazakizumab (anti IL 6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceuticals Inc. (founded 2004). Dr. Smith received his M.B. B.S. and M.D. from the University of London, UK and is a Fellow of the Royal College of Physicians in London.- Jeffrey Smith，于2023年1月加入Zymeworks，担任早期开发高级副总裁，并于2024年1月晋升为执行副总裁兼首席医疗官。他的总部设在爱尔兰都柏林的Zymeworks Inc.欧洲中心。史密斯博士曾在制药行业担任多个高级职位。此前，史密斯博士于2017年3月至2019年10月担任爱尔兰都柏林Alder Biopharmaceuticals Inc.的董事总经理，并于2012年至2017年3月担任美国西雅图Alder Biopharmaceuticals Inc.的转化医学高级副总裁。Smith博士负责eptinezumab（用于偏头痛的抗CGRP抗体）和clazakizumab（用于类风湿性关节炎和癌症恶病质的抗IL-6抗体）的临床开发（I-III期）。史密斯博士也是Alder Biopharmaceutcials Inc（成立于2004年）的创始人。史密斯博士在英国伦敦大学获得了工商管理硕士学位和医学博士学位，并且是伦敦皇家内科医学院的院士。
- Jeffrey Smith joined Zymeworks in January 2023 as Senior Vice President, Early Stage Development and was promoted to Executive Vice President and Chief Medical Officer in January 2024. He is based at European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical indtry. Previoly, Dr. Smith served as the Managing Director of Alder Biopharmaceuticals Inc. in Dublin, Ireland from March 2017 to October 2019, and as Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc. in Seattle, U.S. from 2012 to March 2017. Dr. Smith was responsible for the clinical development (phase I III) of eptinezumab (anti CGRP antibody for migraine) and clazakizumab (anti IL 6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceuticals Inc. (founded 2004). Dr. Smith received his M.B. B.S. and M.D. from the University of London, UK and is a Fellow of the Royal College of Physicians in London.